Kite Pharma is a biopharmaceutical company that specializes in the development of gene therapies for the treatment of multiple cancers. Their primary focus is on developing chimeric antigen receptor (CAR) T-cell therapies, which genetically modify T-cells to recognize and attack cancer cells. Uses: Kite Pharma’s flagship product is Yescarta, which is an FDA-approved CAR-T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (DLBCL). This includes DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is a one-time treatment that involves the extraction of T-cells from the patient’s own body. These T-cells are then engineered to express a CAR that targets CD19, a protein found on the surface of B-cell lymphoma cells. The modified T-cells are then infused back into the patient where they multiply and attack the cancer cells. Dosage: The dosage of Yescarta varies based on the patient’s weight and disease severity. The standard dose for Yescarta is a single infusion of 2-10 x 10^6 CAR-positive viable T-cells per kg of body weight. The infusion is typically given in a hospital or clinical setting, and patients are closely monitored for any adverse reactions. Side Effects: As with any medication, Yescarta may cause side effects. The most common side effects of Yescarta include fever, fatigue, headache, chills, nausea, diarrhea, and decreased appetite. Additionally, Yescarta may cause serious side effects, such as cytokine release syndrome (CRS) and neurologic toxicities. CRS is a systemic inflammatory response that can cause fever, hypotension, and organ dysfunction. Neurologic toxicities can cause confusion, seizures, and other neurologic symptoms. Both CRS and neurologic toxicities can be life-threatening and require immediate medical attention. Interactions: Yescarta has not been evaluated for potential drug-drug interactions. Patients should inform their healthcare providers of all medications, vitamins, and supplements they are taking before starting treatment with Yescarta. Generic: At this time, there is no generic version of Yescarta available. Demographic: Yescarta is approved for use in adult patients with relapsed or refractory large B-cell lymphoma (DLBCL). DLBCL is the most common type of non-Hodgkin lymphoma (NHL) in adults, accounting for approximately 30% of all cases. DLBCL is typically diagnosed in patients over the age of 60, and it affects both men and women equally. Conclusion: Kite Pharma’s Yescarta is a breakthrough treatment for patients with relapsed or refractory large B-cell lymphoma. While Yescarta is highly effective in treating cancer, it may cause serious side effects that require close monitoring and immediate medical attention. Patients should inform their healthcare providers of all medications, vitamins, and supplements they are taking before starting treatment with Yescarta.